Isabelle Mahé/LinkedIn
Aug 1, 2025, 13:11
Isabelle Mahé Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis
Isabelle Mahé, University Professor, Hospital Practitioner in Internal Medicine, shared an insightful post on LinkedIn:
”APICAT Study : reduced dose of apixaban for extended treatment in patient with Cancer associated Thrombosis.
A practice changing study.”
Read the full article here.
Article: ”Apixaban for Cancer-Associated Venous Thromboembolism”
Authors: Zhuo Shao, Xinyu Zhai
Stay updated on the latest scientific advancements in the field of thrombosis with Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 7, 2025, 06:59Stephen Cornelissen is Celebrating an Extraordinary Milestone at Australian Red Cross Lifeblood
-
Nov 7, 2025, 06:56Reza Shojaei on Leadership in the Blood and Plasma Sector
-
Nov 7, 2025, 06:52Rachel Margolis-Goodman Announces Groundbreaking Expension of Versiti Blood Research Institute
-
Nov 7, 2025, 06:46What’s New in HIT from THANZ Webinar Series
-
Nov 7, 2025, 03:30Abdallah Othman About Cardiac Vasculature
-
Nov 7, 2025, 03:29Aabha Divya: Thrilled to Share Our Latest Publication in Annals of Thoracic Surgery Short Reports!
-
Nov 7, 2025, 03:28Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD